Genmab Expands Oncology Pipeline With New First-In-Human GEN1106 Trial

Genmab (Otc) (GMAB) announced an update on their ongoing clinical study.

Genmab has launched a first-in-human study called “First-In-Human, Open-Label, Dose Escalation and Expansion Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of GEN1106 in Participants With Solid Tumors.” The trial aims to test safety and early signs of benefit for GEN1106 in solid tumors, including urothelial cancer, which could open a new growth avenue if results are positive.

The treatment under study is GEN1106, an intravenous biological drug given by infusion. It is designed to target cancer cells in solid tumors and is being tested as an active treatment, with no placebo group in any part of the trial.

The trial is an interventional, Phase 1 cancer study focused on treatment. All patients receive GEN1106, with doses adjusted over time, and there is no blinding, meaning both doctors and patients know what is given.

The design uses sequential dose escalation, followed by dose refinement and expansion in selected cancer types. Randomization may be added only in later parts to compare different dose levels, keeping the focus on finding a safe and effective range rather than head-to-head drug comparisons.

The study started recruitment after first submission on 10 February 2026, marking Genmab’s latest push into early-stage oncology assets. The primary completion date has not been posted yet, but investors should note that Phase 1 oncology studies often take several years before mature readouts.

The last update to the record was submitted on 20 February 2026, signaling that the protocol and recruiting status are current. The estimated overall completion date is not disclosed, highlighting that this is an early, high-risk, high-optionality program rather than an imminent revenue driver.

For investors, the launch of GEN1106 broadens Genmab’s pipeline beyond its existing antibody franchises and may support a higher long-term growth narrative if safety and early activity look promising. However, as a Phase 1 asset, it is unlikely to move GMAB stock on fundamentals near term, and any impact will mainly reflect sentiment around innovation and portfolio depth.

In the wider oncology space, competition in solid tumor biologics is intense, with large players like Merck, Bristol Myers and Roche advancing their own next-generation agents. Success for GEN1106 would strengthen Genmab’s partnering position and justify its R&D spend, while setbacks would be seen as normal early-stage attrition rather than a thesis-breaking event.

Overall, this update signals that Genmab is actively investing in new solid tumor candidates, which supports a long-term, pipeline-driven view of GMAB rather than a short-term catalyst trade. The study is currently recruiting and remains ongoing, with further details and future updates available on the ClinicalTrials.gov portal.

To learn more about GMAB’s potential, visit the Genmab (Otc) drug pipeline page.